Cloudbreak Pharma Inc. Announces Voluntary Withdrawal of IND Application for CBT-009 in China

Key Points from the Announcement

• Cloudbreak Pharma Inc. (Stock Code: 2592) has voluntarily withdrawn its Investigational New Drug (IND) application for CBT-009, one of its core pipeline products, regarding a planned Phase 3 clinical trial in China.
• CBT-009 is a Semi-fluorinated Alkane (SFA+)-based atropine eye drop designed to treat juvenile myopia.
• The IND application was originally submitted to China’s Center for Drug Evaluation (CDE) in December 2025 and accepted in January 2026, following a pre-IND consultation in January 2024.
• After the IND submission, a comparable drug received marketing approval in China, which, together with communications with the CDE, led the company to believe it would be difficult to include China in a Multi-regional Clinical Trial (MRCT) due to different regulatory requirements.
• To mitigate R&D risks and focus resources, the company has decided to withdraw the IND application for the Phase 3 MRCT in China.
• The company will reassess its clinical development strategy for CBT-009, including potential supplementary studies or trial protocol adjustments. Further consultation with the CDE or clinical study resubmission may occur, depending on circumstances.
• Other pipeline assets remain on track: IND applications and R&D for CBT-004 and CBT-199 are progressing as planned. The Phase 3 MRCT for CBT-001 is expected to complete in Q3 2026.
• The company emphasizes that there is no guarantee any of its core products, including CBT-009, will ultimately be successfully developed, launched, or marketed.

Details and Implications for Investors

The voluntary withdrawal of the IND application for CBT-009 in China is a significant development for Cloudbreak Pharma Inc. and its shareholders. The decision comes after the approval of a comparable drug in the Chinese market and challenges stemming from differing regulatory requirements for conducting a placebo-controlled MRCT across various regions.

This move reflects management’s risk mitigation strategy and prudent resource allocation. By withdrawing the IND at this stage, Cloudbreak avoids potential regulatory setbacks and wasted R&D expenditure. However, it may also delay or complicate the timeline for CBT-009’s market entry in China, which could impact future revenues tied to this product.

Investors should also note that the company remains committed to its SFA+ platform and will continue to evaluate opportunities for CBT-009, including possible protocol revisions or supplementary studies to meet regulatory requirements. The company has indicated it may resubmit the application or hold further consultations with the CDE as development progresses.

Cloudbreak’s other core products—CBT-004, CBT-199, and CBT-001—are unaffected by this withdrawal. The Phase 3 MRCT for CBT-001 is on track for completion in the third quarter of 2026, which could serve as a positive catalyst depending on trial outcomes.

The company has issued a warning to shareholders and potential investors: there is no guarantee that CBT-009 or other pipeline products will ultimately be successfully developed, launched, or marketed. Accordingly, investors should exercise caution when dealing in the shares.

Potential Price Sensitivity

The withdrawal of a Phase 3 IND application for a core product is a potentially price-sensitive event. It may signal to the market a delay in product commercialization and revenue realization for CBT-009 in China, possibly impacting investor sentiment and share price in the short term. Conversely, the company’s proactive management of regulatory risk and continued progress in other pipeline products could help offset some negative sentiment.

Further Announcements

Cloudbreak Pharma Inc. has committed to keeping shareholders and potential investors informed of any material developments regarding CBT-009 and other pipeline products through further announcements.

Board Composition

The Board is led by Dr. Ni Jinsong (Chairman, Executive Director, and CEO) and includes both executive, non-executive, and independent non-executive directors with broad industry and scientific experience.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. There is no guarantee that CBT-009 or any other product mentioned will be successfully developed, approved, or marketed. Investors should conduct their own research and exercise caution when making investment decisions.

View CLOUDBREAK-B Historical chart here